Company: RGBP
Filing Date: 2025-12-05
Form Type: 253G1
Source: 0001493152-25-026350
Chunk: 148

Company: Regen BioPharma Inc
Filing Date: 2025-12-05
Form: 253G1
Chunk 148
---
 utilized to repay an aggregate of $152,000 of outstanding principal indedebteness and interest due to Coventry by the Company resulting from a $175,000 Note issued to Coventry on September 12, 2023.

In Connection with the Purchase Agreement the Company issued to Coventry 500,000 common shares (“Commitment Shares”). If The Company has satisfied all the terms of the Note without default the Coventry shall, within 10 calendar days thereafter, return to the Company’s treasury for cancellation 350,000 of the Commitment Shares.

<div align='center'>112</div>

10. CONVERTIBLE NOTES PAYABLE

Convertible notes comprise of below:

|          |     | As of September 30, |         |     |      |         |
|          |     |                2024 |         |     | 2023 |         |
| Lender 1 |     |                     | 200,000 |     |      | 200,000 |
| Lender 2 |     |                     | 100,000 |     |      | 100,000 |
| Lender 3 |     |                     |  50,000 |     |      |  50,000 |
| Lender 4 |     |                     | 100,000 |     |      | 100,000 |
| Lender 5 |     |                     |  49,880 |     |      |  49,880 |
| Lender 6 |     |                     |       - |     |      |  10,000 |
| Total    |     |                   $ | 499,880 |     |    $ | 509,880 |

| i. | On                                                                                                                                     
 May 5, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $200,000                               
 for consideration consisting of $200,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the       
 Note is May 5, 2020. The Note is convertible into the Common Shares of Regen at a price per share (“Conversion Price”)                 
 equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately   
 prior to the date a conversion notice is given by the Lender to Regen or (b) $375 per common share as of the date which is the earlier 
 of: